Please login to the form below

Intercept

This page shows the latest Intercept news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

Latest news

Intercept hit hard as FDA issues Ocaliva safety notice

Intercept claimed an accelerated FDA approval for Ocaliva in May 2016 and followed that with an EMA green light in December. ... Intercept can muster approvals in additional indications such as non-alcoholic steatohepatitis (NASH) for which it is in
BMS claims a win in mid-stage NASH trial

elafibranor and Intercept's Ocaliva (obeticholic acid), which is already on the market for another indication (primary biliary cholangitis).
Intercept gets EU nod for rare liver disease therapy

Intercept gets EU nod for rare liver disease therapy. Ocaliva approved as a combination treatment for primary biliary cholangitis. ... Intercept Pharma now has approval for its Ocaliva drug for primary biliary cholangitis (PBC) therapy Ocaliva on both
Gilead chalks up trial success for new NASH drug

The company is vying with rivals such as Allergan and Intercept Pharmaceuticals in its pursuit of the NASH market. ... Allergan has been building a pipeline of candidates through a series of bolt-on acquisitions including Akarna Therapeutics and Tobira
CHMP backs Intercept's rare liver disease drug

CHMP backs Intercept's rare liver disease drug. Ocaliva on track for EU approval as analysts predict blockbuster sales. ... While PBC is a small indication, Intercept is also developing Ocaliva for non-alcoholic steatohepatitis (NASH) or fatty liver

More from news
Approximately 6 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch June 2016

In Europe Cerus expects to apply for a CE Mark for the Intercept RBC System in the second half of 2016. ... collaboration, licence. 200. Cerus/ BARDA. Intercept, pathogen reduction technology for blood transfusions including Zika virus.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Simon Doyle joins STEM

Doyle - who joins the group from Intercept Pharmaceuticals where he was executive director of commercial operations and marketing - will be at the forefront of a number of key accounts to help
Glenn Sblendorio to retire as president of The Medicines Company

He currently serves as a director at Amicus Therapeutics, Intercept Pharmaceuticals and Ophthotech Corporation.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Blog: 5 ingredients: Multichannel marketing, simplified

Develop your communication for each channel specifically. Intercept testing: show the ad to your mother, your child, a co-worker down the hall.
Market Insights Can Deliver a Better Patient Experience

Our survey, carried out using a mobile research intercept method, found that, unfortunately, memory aids can give patients the false reassurance that they are more compliant than they actually are.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager: Negotiable

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Account Manager – Healthcare Advertising: Salary TBC

Sudler London - Account Director: Competitive

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Medical Writer: Salary is DOE

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Systematic Review Lead- London: Negotiable

Market Access Consultant - Greater Manchester: Negotiable

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Medical Writer - Creative and Scientific Projects: DOE

Senior Medical Writer, MedComms Agency: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director or Senior Account Director: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Healthcare PR Director: £100, 000 – £120, 000 benefits

Subscribe to our email news alerts

PMHub

Add my company

Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....